Clinical validation paved the way to a global partner
In a placebo-controlled Phase 2b study in first-time mothers, tafoxiparin showed a statistically significant effect on preparation for labour. A larger proportion of treated women had a spontaneous onset of labour or achieved a ripe cervix with tafoxiparin alone compared with placebo. The study also showed fewer instrumental deliveries and positive signals regarding birth outcomes.
Following dialogue with regulatory authorities in both the USA and Europe, the development path towards registration-enabling Phase 3 studies has been clarified.
The next major step came in 2026 when Dilafor entered into a binding agreement with Exeltis, a global player in women’s health. Exeltis will fund the continued clinical development and commercialisation of tafoxiparin in the agreed markets.
For KDventures, Dilafor represents an example of long-term life science ownership where scientific and clinical development has progressively reduced project risk and led to industrial validation through a global partner.